LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

CAMBRIDGE, MA, USA I July 30, 2025 I Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

SAN DIEGO, CA, USA I July 30, 2025 I EuMentis Therapeutics, Inc., (“EuMentis”), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

ANN ARBOR, MI, USA I July 30, 2025 I Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the ...

LA JOLLA, CA, USA I July 30, 2025 I AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination ...

(“Be Bio” or “the Company”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was treated with BE-101 in ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit ...

CONSHOHOCKEN, PA, USA I July 30, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive ...